ReviewCommunications biology2025
The pursuit of ultrasensitive phosphoproteomics to unravel signalling in rare cells.
Review in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mapping functional signaling landscapes across the human phosphoproteome.Nature structural & molecular biology · 2026Article
- Phosphoproteomics in Vascular Biology and Disease: Illuminating Signaling in the Vessel.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Multi Omics Integration in Colorectal Cancer: From Molecular Insights to Precision Oncology.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Mass spectrometry-based phosphoproteomic workflows enable routine study of signalling dynamics in contexts where cells are abundant. However, the analysis of cell signalling governed by phosphorylation requires an additional enrichment step which poses a significant challenge when dealing with limited material. The development of sensitive techniques that allow phosphoproteomic analysis of a few hundred cells is increasingly enabling researchers to disambiguate the complexity of protein signalling networks within heterogeneous cell populations. The imminent task at hand is to apply these techniques in research contexts guided by the available biological material to address complex questions about cellular function. Examples range from characterising differential treatment responses in distinct cell populations to investigating rare cell types from primary patient material or in vivo models. To achieve this, adapted protocols need to consider appropriate isolation of specific cells, simplified sample processing to avoid losses, labelling and multiplexing, and optimised analytical methodologies. Here, we discuss these aspects of the workflow, highlighting how innovations from low-input and single-cell proteomics can be adapted to drive low-input phosphoproteomics forward.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.